Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) reported Q2 2017 earnings this Morning, coming in at ($0.09) per share, missing Wall Street’s estimates of ($0.03) per Share. Revenue for the quarter came in at $104.15 million missing the streets estimates of $93.29 million
Analyst Coverage For Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
These are 2 Sell Ratings, 5 Hold Ratings, 6 Buy Ratings .
The current consensus rating for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is Hold (Score: 2.31) with a consensus target price of $46.09 , a potential (12.31% downside)Recent Insider Trading for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
- On 7/24/2017 C Frank Bennett, SVP, sold 10,000 with an average share price of $59.29 per share and the total transaction amounting to $592,900.00.
- On 7/20/2017 Stanley T Crooke, Chairman, sold 11,000 with an average share price of $55.35 per share and the total transaction amounting to $608,850.00.
- On 7/19/2017 Ionis Pharmaceuticals Inc, Major Shareholder, bought 3,125,000 with an average share price of $8.00 per share and the total transaction amounting to $25,000,000.00.
- On 7/17/2017 Stanley T Crooke, Chairman, sold 16,500 with an average share price of $52.45 per share and the total transaction amounting to $865,425.00.
- On 7/3/2017 Brett P Monia, SVP, sold 309 with an average share price of $51.35 per share and the total transaction amounting to $15,867.15.
- On 7/3/2017 Stanley T Crooke, Chairman, sold 16,500 with an average share price of $52.10 per share and the total transaction amounting to $859,650.00.
Recent Trading for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares of Ionis Pharmaceuticals, Inc. closed the previous trading session at 48.97 down -3.59 -6.83% with 1,048,947 shares trading hands.